BIOMAT Database Logo BIOMAT Database Logo

Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency. 2019

Clemens Küpper, and Johanna Heinrich, and Katharina Kamm, and Veit Bücklein, and Simon Rothenfusser, and Andreas Straube
From the Department of Neurology (C.K., J.H., K.K., A.S.), University Hospital, Ludwig Maximilians University; Laboratory for Leukemia Diagnostics (V.B.), Department of Medicine III, University Hospital, Ludwig Maximilians University; and Division of Clinical Pharmacology (S.R.), University Hospital, Ludwig Maximilians University, Munich, Germany. Clemens.Kuepper@med.uni-muenchen.de.

UI MeSH Term Description Entries
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D007968 Leukoencephalopathy, Progressive Multifocal An opportunistic viral infection of the central nervous system associated with conditions that impair cell-mediated immunity (e.g., ACQUIRED IMMUNODEFICIENCY SYNDROME and other IMMUNOLOGIC DEFICIENCY SYNDROMES; HEMATOLOGIC NEOPLASMS; IMMUNOSUPPRESSION; and COLLAGEN DISEASES). The causative organism is JC Polyomavirus (JC VIRUS) which primarily affects oligodendrocytes, resulting in multiple areas of demyelination. Clinical manifestations include DEMENTIA; ATAXIA; visual disturbances; and other focal neurologic deficits, generally progressing to a vegetative state within 6 months. (From Joynt, Clinical Neurology, 1996, Ch26, pp36-7) Encephalitis, JC Polyomavirus,Progressive Multifocal Leukoencephalopathy,JC Polyomavirus Encephalopathy,Encephalopathies, JC Polyomavirus,Encephalopathy, JC Polyomavirus,JC Polyomavirus Encephalitis,Leukoencephalopathies, Progressive Multifocal,Multifocal Leukoencephalopathies, Progressive,Multifocal Leukoencephalopathy, Progressive,Progressive Multifocal Leukoencephalopathies
D008297 Male Males
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000081207 Primary Immunodeficiency Diseases Genetic immunologic deficiency diseases and syndromes due to mutations in genes involved in IMMUNITY generally characterized by an increased susceptibility to infectious diseases. They are often associated with AUTOIMMUNE DISEASE manifestations. Congenital Immunodeficiency Disease,Congenital Immunodeficiency Diseases,Congenital Immunodeficiency Disorder,Congenital Immunodeficiency Disorders,Congenital Immunodeficiency Syndrome,Congenital Immunodeficiency Syndromes,Inherited Immunodeficiency Disease,Inherited Immunodeficiency Diseases,Inherited Immunodeficiency Disorder,Inherited Immunodeficiency Disorders,Inherited Immunodeficiency Syndrome,Inherited Immunodeficiency Syndromes,Primary Antibody Deficiencies,Primary Antibody Deficiency Disorder,Primary Antibody Deficiency Disorders,Primary Antibody Deficiency Syndrome,Primary Antibody Deficiency Syndromes,Primary Immune Deficiency,Primary Immune Deficiency Disease,Primary Immune Deficiency Diseases,Primary Immune Deficiency Disorder,Primary Immune Deficiency Disorders,Primary Immune Deficiency Syndrome,Primary Immune Deficiency Syndromes,Primary Immunodeficiency Disease,Primary Immunodeficiency Disorder,Primary Immunodeficiency Disorders,Primary Immunodeficiency Syndromes,Antibody Deficiency, Primary,Deficiency, Primary Immune,Immune Deficiency, Primary,Immunodeficiency Disease, Congenital,Immunodeficiency Disease, Inherited,Immunodeficiency Disease, Primary,Immunodeficiency Diseases, Congenital,Immunodeficiency Diseases, Inherited,Immunodeficiency Diseases, Primary,Immunodeficiency Disorder, Congenital,Immunodeficiency Disorder, Inherited,Immunodeficiency Disorder, Primary,Immunodeficiency Disorders, Congenital,Immunodeficiency Disorders, Inherited,Immunodeficiency Syndrome, Congenital,Immunodeficiency Syndrome, Inherited,Immunodeficiency Syndrome, Primary,Immunodeficiency Syndromes, Congenital,Immunodeficiency Syndromes, Inherited,Immunodeficiency Syndromes, Primary,Inherited Immunodeficiency Syndrome,Primary Antibody Deficiency,Primary Immune Deficiencies,Primary Immunodeficiency Syndrome
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D061067 Antibodies, Monoclonal, Humanized Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab. Antibodies, Humanized,Humanized Antibodies

Related Publications

Clemens Küpper, and Johanna Heinrich, and Katharina Kamm, and Veit Bücklein, and Simon Rothenfusser, and Andreas Straube
Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy.
April 2019, The New England journal of medicine,
Clemens Küpper, and Johanna Heinrich, and Katharina Kamm, and Veit Bücklein, and Simon Rothenfusser, and Andreas Straube
Single-Dose Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy.
July 2021, Neurology(R) neuroimmunology & neuroinflammation,
Clemens Küpper, and Johanna Heinrich, and Katharina Kamm, and Veit Bücklein, and Simon Rothenfusser, and Andreas Straube
Treatment of Progressive Multifocal Leukoencephalopathy with Pembrolizumab.
April 2019, The New England journal of medicine,
Clemens Küpper, and Johanna Heinrich, and Katharina Kamm, and Veit Bücklein, and Simon Rothenfusser, and Andreas Straube
Pembrolizumab treatment for progressive multifocal leukoencephalopathy in a patient with Human Immunodeficiency Virus infection.
October 2020, Enfermedades infecciosas y microbiologia clinica (English ed.),
Clemens Küpper, and Johanna Heinrich, and Katharina Kamm, and Veit Bücklein, and Simon Rothenfusser, and Andreas Straube
Progressive Multifocal Leukoencephalopathy in Patient with Primary Immunodeficiency Syndrome.
January 2022, Neurology India,
Clemens Küpper, and Johanna Heinrich, and Katharina Kamm, and Veit Bücklein, and Simon Rothenfusser, and Andreas Straube
Visual loss due to progressive multifocal leukoencephalopathy in a congenital immunodeficiency disorder.
September 2001, Archives of ophthalmology (Chicago, Ill. : 1960),
Clemens Küpper, and Johanna Heinrich, and Katharina Kamm, and Veit Bücklein, and Simon Rothenfusser, and Andreas Straube
Stabilization of Progressive Multifocal Leukoencephalopathy After Pembrolizumab Treatment.
July 2020, The Neurohospitalist,
Clemens Küpper, and Johanna Heinrich, and Katharina Kamm, and Veit Bücklein, and Simon Rothenfusser, and Andreas Straube
PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy.
January 2021, Therapeutic advances in neurological disorders,
Clemens Küpper, and Johanna Heinrich, and Katharina Kamm, and Veit Bücklein, and Simon Rothenfusser, and Andreas Straube
Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy in China.
December 2023, Journal of neurovirology,
Clemens Küpper, and Johanna Heinrich, and Katharina Kamm, and Veit Bücklein, and Simon Rothenfusser, and Andreas Straube
Pembrolizumab for treatment of progressive multifocal leukoencephalopathy in primary immunodeficiency and/or hematologic malignancy: a case series of five patients.
February 2022, Journal of neurology,
Copied contents to your clipboard!